| Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery … C von Birgelen, MM Kok, LC van der Heijden, PW Danse, CE Schotborgh, ... The Lancet 388 (10060), 2607-2617, 2016 | 244 | 2016 |
| Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt–chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers … C von Birgelen, P Zocca, RA Buiten, GAJ Jessurun, CE Schotborgh, ... The Lancet 392 (10154), 1235-1245, 2018 | 131 | 2018 |
| Patient preference for radial versus femoral vascular access for elective coronary procedures: the PREVAS study MM Kok, MGM Weernink, C von Birgelen, A Fens, LC van der Heijden, ... Catheterization and Cardiovascular Interventions 91 (1), 17-24, 2018 | 92 | 2018 |
| Outcomes in patients treated with thin-strut, very thin-strut, or ultrathin-strut drug-eluting stents in small coronary vessels: a prespecified analysis of the randomized BIO … RA Buiten, EH Ploumen, P Zocca, CJM Doggen, LC Van Der Heijden, ... JAMA cardiology 4 (7), 659-669, 2019 | 70 | 2019 |
| Small-vessel treatment with contemporary newer-generation drug-eluting coronary stents in all-comers: insights from 2-year DUTCH PEERS (TWENTE II) randomized trial LC van der Heijden, MM Kok, PW Danse, AR Schramm, M Hartmann, ... American heart journal 176, 28-35, 2016 | 65 | 2016 |
| Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT P Zocca, LC van der Heijden, MM Kok, MM Löwik, M Hartmann, MG Stoel, ... EuroIntervention 13 (10), 1168-1176, 2017 | 58 | 2017 |
| Thin, very thin, or ultrathin strut biodegradable or durable polymer-coated drug-eluting stents: 3-year outcomes of BIO-RESORT RA Buiten, EH Ploumen, P Zocca, CJM Doggen, PW Danse, ... JACC: Cardiovascular Interventions 12 (17), 1650-1660, 2019 | 57 | 2019 |
| Five-year outcome after implantation of zotarolimus-and everolimus-eluting stents in randomized trial participants and nonenrolled eligible patients: a secondary analysis of a … C von Birgelen, LC Van Der Heijden, MWZ Basalus, MM Kok, H Sen, ... JAMA cardiology 2 (3), 268-276, 2017 | 52 | 2017 |
| 5-year outcome following randomized treatment of all-comers with zotarolimus-eluting resolute integrity and everolimus-eluting PROMUS element coronary stents: final report of … P Zocca, MM Kok, K Tandjung, PW Danse, GAJ Jessurun, RWM Hautvast, ... Cardiovascular Interventions 11 (5), 462-469, 2018 | 50 | 2018 |
| Impact of severe lesion calcification on clinical outcome of patients with stable angina, treated with newer generation permanent polymer-coated drug-eluting stents: a patient … J Huisman, LC van der Heijden, MM Kok, PW Danse, GAJ Jessurun, ... American heart journal 175, 121-129, 2016 | 47 | 2016 |
| Two-year clinical outcome of all-comers treated with three highly dissimilar contemporary coronary drug-eluting stents in the randomised BIO-RESORT trial MM Kok, RA Buiten, PW Danse, CE Schotborgh, M Scholte, M Hartmann, ... EuroIntervention 14 (8), 915-923, 2018 | 44 | 2018 |
| Prediabetes and its impact on clinical outcome after coronary intervention in a broad patient population MM Kok, C von Birgelen, N Sattar, MM Löwik, PW Danse, CE Schotborgh, ... EuroIntervention 14 (9), e1049-e1056, 2018 | 41 | 2018 |
| Two-year outcome after treatment of severely calcified lesions with newer-generation drug-eluting stents in acute coronary syndromes: a patient-level pooled analysis from … J Huisman, LC van der Heijden, MM Kok, PW Danse, GAJ Jessurun, ... Journal of cardiology 69 (4), 660-665, 2017 | 32 | 2017 |
| High bleeding risk patients with acute coronary syndromes treated with contemporary drug-eluting stents and Clopidogrel or Ticagrelor: Insights from CHANGE DAPT P Zocca, MM Kok, LC van der Heijden, KG van Houwelingen, ... International journal of cardiology 268, 11-17, 2018 | 31 | 2018 |
| “Silent” diabetes and clinical outcome after treatment with contemporary drug-eluting stents: the BIO-RESORT Silent Diabetes study C von Birgelen, MM Kok, N Sattar, P Zocca, C Doelman, GD Kant, ... Cardiovascular Interventions 11 (5), 448-459, 2018 | 28 | 2018 |
| Three-year safety and efficacy of treating all-comers with newer-generation Resolute Integrity or PROMUS Element stents in the randomised DUTCH PEERS (TWENTE II) trial LC van der Heijden, MM Kok, MM Löwik, PW Danse, GAJ Jessurun, ... EuroIntervention 12 (17), 2128-2131, 2017 | 27 | 2017 |
| sex difference in chest pain after implantation of newer generation coronary drug-eluting stents: a patient-level pooled analysis from the TWENTE and DUTCH PEERS trials MM Kok, LC van der Heijden, H Sen, PW Danse, MM Löwik, RL Anthonio, ... JACC: Cardiovascular Interventions 9 (6), 553-561, 2016 | 23 | 2016 |
| Three-year clinical outcome of patients with bifurcation treatment with second-generation Resolute and Xience V stents in the randomized TWENTE trial MK Lam, H Sen, KG van Houwelingen, MM Löwik, LC van der Heijden, ... American heart journal 169 (1), 69-77, 2015 | 22 | 2015 |
| Impact of prediabetes and diabetes on 3-year outcome of patients treated with new-generation drug-eluting stents in two large-scale randomized clinical trials EH Ploumen, TH Pinxterhuis, P Zocca, A Roguin, RL Anthonio, ... Cardiovascular diabetology 20, 1-11, 2021 | 18 | 2021 |
| Are component endpoints equal? A preference study into the practice of composite endpoints in clinical trials MCW Vaanholt, MM Kok, C von Birgelen, MGM Weernink, JA van Til Health Expectations 21 (6), 1046-1055, 2018 | 16 | 2018 |
